Immunovant, Inc. (IMVT) bonds
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Immunovant reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Immunovant's 10-K for the period ended Dec 17, 2019
| Issue | Coupon | Amount issued |
|---|---|---|
| BVF Convertible Promissory Notes Convertible | – | $10.00M |
| Convertible Promissory Notes Convertible | – | $35.00M |
| RTW Convertible Promissory Notes Convertible | 5.00% | $22.50M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
See a number that looks wrong?